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The identification of cell types of origin for cancer has
important implications for tumor stratification and
personalized treatment. For prostate cancer, the
cell of origin has been intensively studied, but it has
remained unclear whether basal or luminal epithelial
cells, or both, represent cells of origin under physio-
logical conditions in vivo. Here, we use a novel line-
age-tracing strategy to assess the cell of origin in a
diverse range of mouse models, including Nkx3.1+/;
Pten+/, Pten+/, Hi-Myc, and TRAMP mice, as well
as a hormonal carcinogenesis model. Our results
show that luminal cells are consistently the observed
cell of origin for each model in situ; however, ex-
planted basal cells from these mice can generate
tumors in grafts. Consequently, we propose that
luminal cells are favored as cells of origin in many
contexts, whereas basal cells only give rise to
tumors after differentiation into luminal cells.INTRODUCTION
The identification of cell types of origin for cancer is significant,
since distinct cell populations within a tissue may give rise to
different cancer subtypes distinguished by their histopatholog-
ical phenotypes and patient outcomes (Blanpain, 2013; Vis-
vader, 2009, 2011; Wang et al., 2013). Numerous studies have
investigated the cell of origin by introducing an oncogenic insult
within a defined cell type to determine whether these cells can
give rise to cancer. However, such approaches are potentially
limited, as the cell type of origin may be dependent on the
specific oncogenic insult and/or the model system. To date, no
studies have systematically addressed which cell types can
serve as cells of origin in multiple contexts of tumor initiation.
In human and mouse prostate epithelium, luminal and basal
cells are the two major cell types, together with rare neuroendo-
crine cells (Shen and Abate-Shen, 2010). Lineage tracing has
shown that luminal and basal cells in the adult mouse prostate
represent distinct populations that are mostly self-sustaining
(Choi et al., 2012; Lu et al., 2013; Wang et al., 2013). Notably,Cell Relineage-marked basal cells rarely generate luminal cells during
adult tissue homeostasis but display plasticity under the influ-
ence of inductive embryonic urogenital mesenchyme in grafting
assays, acquiring facultative progenitor properties and gener-
ating luminal cells (Choi et al., 2012; Lu et al., 2013; Wang
et al., 2013).
For prostate cancer, previous studies have reached differing
conclusions regarding the cell type(s) of origin (Goldstein and
Witte, 2013;Wang and Shen, 2011; Xin, 2013). Although prostate
adenocarcinoma has a luminal phenotype, both basal and
luminal cells have been proposed to represent cells of origin. In
particular, transformed human basal cells can give rise to pros-
tate cancer in renal grafting models (Goldstein et al., 2010;
Stoyanova et al., 2013; Taylor et al., 2012), whereas a luminal
stem cell population identified in the regressed mouse prostate
can act as a cell of origin in vivo (Wang et al., 2009). More
recently, lineage tracing in mice in which the Pten tumor sup-
pressor was specifically deleted in either basal or luminal cells
has shown that both cell types can act as cells of origin (Choi
et al., 2012; Lu et al., 2013; Wang et al., 2013).
However, it remains unclear whether basal or luminal cells, or
both, represent cell types of origin in the context of Pten deletion
occurring throughout the prostate epithelium or whether the cell
of origin might vary depending upon specific oncogenic events.
We have investigated this issue using a novel lineage-tracing
strategy in a diverse range of mouse models that recapitulate
important features of human prostate tumorigenesis. Our results
indicate that luminal cells are consistently favored as cells of
origin for prostate cancer.
RESULTS
To determine the cell of origin for amousemodel of prostate can-
cer, we performed lineagemarking of either basal or luminal cells
in apparently normal tissue to determine whether their progeny
contribute to the tumors that subsequently arise (Figure 1). Since
the lineage-tracing methodology uses inducible Cre recombi-
nase, we analyzed mouse models in which the tumor phenotype
is not driven by Cre. We used the CK5-CreERT2 driver (Rock
et al., 2009) for lineage tracing of basal cells and the PSA-
CreERT2 (Ratnacaram et al., 2008) or CK8-CreERT2 (Van Key-
meulen et al., 2011) drivers for tracing of luminal cells, together
with the R26R-YFP reporter (Srinivas et al., 2001). Tamoxifenports 8, 1339–1346, September 11, 2014 ª2014 The Authors 1339
Figure 1. Experimental Design for Analysis
of Cell of Origin
The inducible CK5-CreERT2 driver can lineage
mark basal cells by YFP expression in different
prostate cancer models prior to overt cancer for-
mation. Similarly, the inducible PSA-CreERT2 and
CK8-CreERT2 drivers can mark luminal cells in
phenotypically normal epithelium. The presence of
YFP+ cell clusters in subsequent PIN/cancer le-
sions indicates that the marked cell type acts as
the cell of origin in the mouse model analyzed.induction for lineagemarking was performed in young adult male
mice at 7 weeks of age, when the basal and luminal lineages
have been established as largely self-sustaining compartments
(Choi et al., 2012; Ousset et al., 2012; Wang et al., 2013). Contri-
bution of cells marked by the CK5-CreERT2 driver to tumors
would imply that basal cells were the cell of origin, whereas tu-
mor cells marked by the PSA-CreERT2 or CK8-CreERT2 drivers
would indicate a luminal origin (Figure 1). Notably, our approach
dissociates the time of lineage marking from the onset of tumor-
igenesis and allows multiple models to be analyzed using the
same overall strategy.
In control experiments to examine the specificity of the induc-
ible Cre drivers in a wild-type background, we found that CK5-
CreERT2; R26R-YFP (which we denote CK5-trace) strictly marks
basal cells with 23.6% efficiency, while PSA-CreERT2; R26R-
YFP (PSA-trace) marks luminal cells with 11.5% efficiency and
CK8-CreERT2; R26R-YFP (CK8-trace) marks 4.1% of luminal
cells (Tables S1L, S1N, and S1P), consistent with previous
studies (Ousset et al., 2012; Ratnacaram et al., 2008; Wang
et al., 2013). Importantly, the percentage of lineage-marked cells
in the CK5-trace and PSA-trace mice does not change between
2 months of age, shortly after labeling, and 6 months of age,
when most of our tumor analyses are mostly performed (Fig-
ure S1; Tables S2A and S2B), indicating that the lineage-marked
cell populations are stable in a nontumorigenic background.
We first investigated the cell of origin for the high-grade pros-
tatic intraepithelial neoplasia (PIN) lesions in the Nkx3.1+/;
Pten+/ (which we denote NP) model that is heterozygous for
null alleles of the Nkx3.1 homeobox gene and of Pten (Kim
et al., 2002). As reported previously, the anterior prostate (AP)
and dorsolateral prostate (DLP) of NP mice appear normal at
2 months of age (Figures 2E and 2J) but frequently display1340 Cell Reports 8, 1339–1346, September 11, 2014 ª2014 The Authorshigh-grade PIN/carcinoma lesions at
6 months (Figures 2F and 2K). Quantita-
tion of initial lineagemarking inCK5-trace;
NP mice and PSA-trace; NP mice re-
vealed similar efficiencies as mice with
a wild-type background (Figures 2B,
2C, and 2Y; Tables S1A and S1B).
Notably, in tumor lesions of CK5-trace;
NP mice at 6 months of age, we found
that yellow fluorescent protein (YFP)+
cells in clusters (defined as containing
at least three YFP+ cells) were rarely
observed (0.5%, n = 6 mice) (Figures2G, 2L, and 2Y; Figures S2A and S2D; Table S1A), while the per-
centage of YFP+ cells in untransformed regions was unaffected
(Figures S3A–S3C; Table S2C). In contrast, 10.8% of the cells
in the tumor lesions of PSA-trace; NP mice (n = 4) and 4.5% of
the cells in tumor lesions of CK8-trace; NP mice (n = 3) were
YFP+ (Figures 2H, 2I, 2M, 2N, and 2Y; Figures S2B, S2C, S2E,
and S2F; Tables S1B, S1C, and S1P). Furthermore, we found
that YFP+ clusters were also rare in PIN lesions of 6-month-old
CK5-trace; Pten+/ mice, whereas the frequency of YFP+ cells
was unchanged in nontumor regions (n = 3) (Figures S3D, S3E,
S4A, S4B, S4D, S4E, and S4G; Tables S1D and S2D). However,
the percentage of YFP+ cells in PIN lesions of PSA-trace; Pten+/
mice (n = 3) was similar to the percentage initially marked by
the PSA-CreERT2 inducible driver (Figures S4C, S4F, and S4G;
Table S1E).
Next, we examined the transgenic ARR2/probasin-Myc (Hi-
Myc) model, in which expression of c-Myc is driven in both
luminal and basal compartments, leading to invasive adenocar-
cinoma (Ellwood-Yen et al., 2003). Consistent with previous
studies (Ellwood-Yen et al., 2003), the histology of the AP in
Hi-Myc mice was mostly normal at 2 months of age (Figure 2O),
although the DLP and ventral prostate (VP) were hyperplastic
(Figures S4H and S4K). In the PIN/carcinoma lesions in the AP
of CK5-trace; Hi-Myc mice at 6 months, YFP+ cell clusters
were rare, whereas the percentage of YFP+ basal cells in un-
transformed regions was unaffected (n = 5 mice) (Figures 2P,
2Q, and 2Z; Figures S2G, S3F, and S3G; Tables S1F and S2E).
In contrast, 13.1% of the cells within the PIN/carcinoma lesions
of 6-month-old PSA-trace; Hi-Myc mice (n = 6) were YFP+,
similar to the initial percentage (12.6%) of luminal cells marked
at 2 months (Figures 2R and 2Z; Figure S2H; Table S1G).
Similarly, YFP+ cells were present in PIN/carcinoma lesions of
Figure 2. Luminal Cells Are Favored Cells of Origin in the NP, Hi-Myc, and TRAMP Models
(A) Experimental time course.
(B) Lineage marking of basal cells (arrowheads) in the AP of CK5-trace; NP mice at 2 months of age.
(C and D) Marking of luminal cells (arrows) in the AP of PSA-trace; NP mice (C) or CK8-trace mice (D) at 2 months.
(E, F, J, and K) H&E staining of NP prostates shows normal histology at 2 months and PIN/carcinoma lesions at 6 months.
(G and L) Clusters of YFP+ cells are rarely detected in CK5-trace; NP tumor lesions at 6 months.
(H, I, M, and N) YFP+ cell clusters in tumor lesions of PSA-trace; NP (H and M) and CK8-trace; NP (I and N) mice at 6 months.
(O and P) Normal AP histology in Hi-Myc mice at 2 months (O) and PIN/carcinoma lesions at 6 months (P).
(Q) Absence of YFP+ cell clusters in CK5-trace; Hi-Myc tumor lesions in the AP at 6 months.
(R and S) YFP+ cell clusters in tumor lesions of PSA-trace; Hi-Myc mice (R) and CK8-trace; Hi-Myc mice (S) at 6 months.
(T and U) Normal histology of the AP in TRAMP mice at 2 months (T) and carcinoma at 5 months (U).
(V) Absence of YFP+ cell clusters in CK5-trace; TRAMP AP tumor lesions at 5 months.
(W and X) YFP+ clusters in AP tumor lesions of PSA-trace; TRAMP (W) and CK8-trace; TRAMP (X) mice at 5 months.
(Y–A0 ) Percentage of YFP+ cells in NP (Y), Hi-Myc (Z), and TRAMP (A0) models; Nor = normal, Tum = tumor; **p < 0.001 by Student’s t test; error bars are 1 SD.
Arrowheads in (G), (L), (Q), and (V) indicate marked basal cells. Scale bars correspond to 50 mm in (B)–(D), (G)–(I), (L)–(N), (Q)–(S), and (V)–(X) and 100 mm in (E), (F),
(J), (K), (O), (P), (T), and (U). See also Figures S1–S4.
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CK8-trace; Hi-Mycmice (n = 4) in proportion to the initial luminal
marking efficiency (Figures 2S and 2Z; Figure S2I; Tables S1H
and S1P). Similar results were found in the DLP and VP of
CK5-trace; Hi-Myc and PSA-trace; Hi-Myc mice (Figures
S4H–S4M).
We also investigated the TRAMP model, which expresses the
SV40 large T antigen under the control of the probasin promoter,
giving rise to aggressive tumors (Greenberg et al., 1995). We
found that the AP in TRAMP mice appeared mostly normal at
2 months but developed invasive, poorly differentiated adeno-
carcinoma by 5 months (Figures 2T and 2U). In tumor lesions
of CK5-trace; TRAMP mice (n = 4), YFP+ cell clusters were not
observed, whereas the frequency of YFP+ cells in nontumor re-
gions was unaffected (Figures 2V and 2A0; Figures S2J, S3H,
and S3I; Tables S1I and S2F). However, YFP+ cell clusters
were found in tumor lesions of PSA-trace; TRAMP mice (n = 5)
and CK8-trace; TRAMP mice (n = 3) in percentages similar to
the initial luminal marking efficiencies (Figures 2W, 2X, and 2A0;
Figures S2K and S2L; Tables S1J, S1K, and S1P). Similar results
were observed in the DLP and VP of TRAMP mice, although
these lobes were already hyperplastic at 2 months of age (Fig-
ures S4N–S4S). Taken together, these findings show that luminal
cells are the favored cell of origin in each of the genetically engi-
neered mouse models examined.
Given the potential caveat that cancer initiation might occur
prior to adulthood in these genetically engineered models, we
investigated the cell of origin in a hormonal carcinogenesis para-
digm (Ricke et al., 2008; Wang et al., 2000), in which lineage
marking unequivocally takes place prior to prostate tumor initia-
tion (Bosland et al., 1995; Noble, 1977; Ricke et al., 2008; Wang
et al., 2000). After lineage marking of basal cells in CK5-trace
mice or luminal cells in PSA-trace and CK8-trace mice (Figures
3A–3D; Tables S1L, S1N, and S1P), we treated the mice with a
combination of testosterone (T) and estradiol-17b (E2) for
4 months, resulting in formation of low-grade PIN lesions in all
prostate lobes (Figures 3E, 3I, and 3M). Using this protocol, we
found that YFP+ clusters were rare in PIN lesions of CK5-trace
mice (n = 5), while the frequency of YFP+ cells was unaffected
in untransformed regions (Figures 3F, 3J, 3N, and 3Q; Figures
S2M, S2P, S2S, S3J, and S3K; Tables S1M and S2G). In
contrast, YFP+ clusters were present in PIN lesions of PSA-trace
(n = 4) and CK8-trace mice (n = 3) (Figures 3G, 3H, 3K, 3L, 3O,
3P; Figures S2N, S2O, S2Q, S2R, S2T, and S2U), with the per-
centage of YFP+ cells similar to the initial efficiency of luminal
cell marking (Figure 3Q; Tables S1O and S1Q). These results
indicate that carcinogenesis induced by T+E2 treatment leads
to prostate cancer initiation from luminal cells.
Previous studies have concluded that basal cells are cells of
origin for human prostate cancer using renal grafting methods
(Goldstein et al., 2010; Stoyanova et al., 2013; Taylor et al.,
2012). To determine whether the potential discrepancy between
these studies and our findings might be due to the different
methodologies employed, we tested whether basal cells in our
mouse models of prostate cancer could give rise to tumors after
renal grafting. We performed tamoxifen induction of CK5-trace;
Hi-Myc mice at 7 weeks of age and isolated basal cells by flow
sorting for YFP (Figures 4A and 4B). The sorted basal cells
were recombined with rat urogenital sinus mesenchyme and1342 Cell Reports 8, 1339–1346, September 11, 2014 ª2014 The Augrafted under the renal capsule of immunodeficient NOD.Cg-
Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice, followed by analysis
after 3 months (Figure 4C). We observed extensive regions of
YFP+ epithelium, which contained PIN lesions that were mostly
composed of luminal cells, indicating that basal to luminal
differentiation had taken place (Figures 4D–4F). We obtained
similar results for basal cells isolated from CK5-trace; TRAMP
mice (Figures 4G–4I), as well as from CK5-trace; Pten+/ mice,
in which the graft PIN lesions were also positive for phospho-
Akt (Figures 4J–4L). Finally, we performed renal grafting of
YFP+ basal cells isolated from tamoxifen-induced CK5-trace
mice, followed by treatment of the NOG graft recipients with
T+E2 for 3 months (Figure 4M). In the resulting grafts, marked
basal cells could give rise to PIN lesions that mostly contained
luminal cells (Figures 4N and 4O). Taken together, our results
show that prostate basal cells are not favored as the cell of origin
in their native microenvironment for any of the mouse models
analyzed but nonetheless can give rise to tumors in renal grafts.
DISCUSSION
In principle, the cell of origin for cancermight be context specific,
depending upon the oncogenic pathways being activated. In our
studies, we have employed a novel lineage-tracing methodology
for systematic assessment of the cell of origin for prostate can-
cer in a diverse range of mouse models. Using this ‘‘agnostic’’
lineage-tracing approach, we have unexpectedly found that
luminal epithelial cells are consistently observed as the cell of
origin.
Overall, we have analyzed a representative sample of widely
used mouse models of human prostate cancer (Irshad and
Abate-Shen, 2013; Ittmann et al., 2013; Shappell et al., 2004).
However, there may be specific caveats associated with each
model; for example, tumor initiation might conceivably occur in
basal cells prior to 7 weeks of age in the transgenic models, re-
sulting in early basal-to-luminal differentiation that would escape
lineage marking. This possibility seems unlikely, since all tumor
initiation would have to occur prior to 7 weeks of age to avoid
detection of subsequent tumor formation from basal cells by
lineage tracing. Nonetheless, our analysis has yielded the
remarkably consistent result that luminal cells are favored as
the cell of origin, and consequently we believe that this finding
is likely to reflect the biology of prostate cancer, rather than a
coincidence of intrinsic biases in each model. However, we
note that basal cells could nonetheless act as cells of origin for
prostate adenocarcinoma in other experimental contexts. In
addition, the ability of inflammation to enhance basal-to-luminal
differentiation in vivo (Kwon et al., 2014) suggests that alterations
of the tissue microenvironment could influence the cell of origin
(Goldstein and Witte, 2013).
To date, the cell of origin has usually been assayed by condi-
tional gene targeting to generate oncogenic insults within a spe-
cific cell type. However, if the targeted cell type is a stem/
progenitor cell, it can be difficult to discern whether tumor initia-
tion takes place within the stem/progenitor itself or insteadwithin
its differentiated progeny. In this situation, it can be useful to
distinguish between a ‘‘cell of origin’’ and a ‘‘cell of mutation’’
as distinct entities (Liu et al., 2011; Liu and Zong, 2012). Inthors
Figure 3. Luminal Cells Are the Favored Cell of Origin of Tumors Induced by T+E2 Hormonal Treatment
(A) Experimental time course.
(B–D) Lineage marking of basal (arrowheads) and luminal cells in control CK5-trace (B), PSA-trace (C), and CK8-trace (D) mice.
(E, I, and M) PIN lesions in mice after T+E2 treatment.
(F, J, and N) YFP+ cell clusters are rarely detected in CK5-trace PIN lesions after T+E2 treatment; arrowheads indicate marked basal cells.
(G, H, K, L, O, and P) YFP+ clusters in PIN lesions of PSA-trace (G, K, O) and CK8-trace (H, L, P) mice after T+E2 treatment.
(Q) Percentage of YFP+ cells. Cont, control untreated; T+E2, treated. **p < 0.001 by Student’s t test. Error bars are 1 SD.
Scale bars indicate 50 mm. See also Figures S2 and S3.particular, a progenitor that initially acquires a mutation may not
directly transform and hence be a ‘‘cell of mutation,’’ while its
lineage-restricted progeny may inherit the mutation and subse-
quently undergo oncogenic transformation and thus would
represent a ‘‘cell of origin.’’ For example, lineage tracing of gli-
omas in a p53; Nf1 mouse model has shown that neural stem
cells act as a cell of mutation, whereas their descendant oligo-
dendrocyte progenitors correspond to the cell of origin (Liu
et al., 2011).
In this regard, prostate basal cells removed from their normal
tissue microenvironment can acquire facultative bipotential pro-Cell Regenitor properties after combination with embryonic urogenital
mesenchyme, resulting in the differentiation of luminal cells
(Goldstein et al., 2008; Lawson et al., 2007, 2010; Wang et al.,
2013), while transformed basal cells give rise to luminal tumors
in renal grafts (Goldstein et al., 2010; Stoyanova et al., 2013; Tay-
lor et al., 2012). Our findings are consistent, since lineage-
marked basal cells in each of our mouse models can give rise
to prostate cancer in the context of renal grafts. Consequently,
we propose that mutated basal cells do not usually act as a
cell of origin in prostate tissue in situ but can function as a cell
of mutation in renal grafts by acquiring facultative progenitorports 8, 1339–1346, September 11, 2014 ª2014 The Authors 1343
Figure 4. Basal Cells Can Give Rise to Prostate Cancer in Renal Grafts
(A) Experimental design.
(B) Representative flow-sort of YFP+ basal cells (2.8% of total prostate cells) from CK5-trace; Hi-Myc mice.
(C) Kidney from recipient NOG mouse containing graft with YFP fluorescence (arrow).
(D–I) Grafted basal cells from CK5-trace; Hi-Myc (D–F) or CK5-trace; TRAMP (G–I) mice generate PIN lesions (D and G), which contain mostly luminal cells (E and
H) and some basal cells (arrowheads, F and I).
(J–L) Basal cells from CK5-trace; Pten+/ mice generate PIN lesions (J) that contain mostly luminal cells (K) and express phospho-Akt (L).
(M) Experimental design for T+E2 treatment of grafts.
(N and O) Grafted basal cells give rise to PIN lesions (N) that contain mostly luminal cells (O) after T+E2 treatment.
Scale bars correspond to 25 mm in (E), (F), (H), (I), and (K), 5 mm in (C), and 50 mm in (D), (G), (J), (N), and (O).properties and thereby generating luminal progeny that are
authentic cells of origin.
Notably, previous studies have shown that targeted deletion of
Pten in basal cells results in formation of tumors in situ, albeit
with a temporal delay that appears to be associated with1344 Cell Reports 8, 1339–1346, September 11, 2014 ª2014 The Aubasal-to-luminal differentiation, and which are less aggressive
than tumors arising from targeting of luminal cells (Choi et al.,
2012; Wang et al., 2013). Interestingly, PIN lesions arose from
targeted basal cells by 3 months of age, in contrast with the
absence of contribution from lineage-marked basal cells in NPthors
and Pten+/ mice. These findings are potentially consistent with
a ‘‘competition’’ model, which is not mutually exclusive with the
cell of mutation model. Thus, if Pten loss occurs in both luminal
and basal cells, transformed luminal cells might emerge before
basal cells can be transformed, and might suppress subsequent
basal cell transformation in a non-cell-autonomous manner.
Finally, our finding that luminal cells are the favored cell of
origin in multiple mouse models raises the possibility that most
human prostate adenocarcinomas arise from luminal cells. In
particular, cytological examination of human PIN lesions sug-
gests that early initiating events occur in luminal cells, including
c-Myc upregulation and telomere elongation (Gurel et al., 2008;
Meeker et al., 2002). Moreover, human prostate luminal cells
may be prone to cancer initiation due to a decreased DNA dam-
age response (Ja¨a¨maa et al., 2010). Our results also imply that
cell of origin analyses for human cancer may be inherently diffi-
cult using grafting assays, due to the plasticity of basal cells.
Instead, approaches such as retrospective lineage tracing using
mitochondrialmutationsmay provide insight into humanprostate
cancer origins (Blackwood et al., 2011; Gaisa et al., 2011). Since
the cell of origin may be a critical factor in conferring aggressive-
ness in prostate cancer (Wang et al., 2013), these and other ap-
proaches to identify cell types of origin are likely to be important
for biomarker identification and disease prognosis.
EXPERIMENTAL PROCEDURES
Mouse Procedures
Mouse lines were maintained on an inbred C57BL/6N or mixed C57BL/6N-
129S6/SvEvTac background. Primer sequences for genotyping are listed in
Table S2. For tamoxifen induction, mice were administered 9 mg/40 g tamox-
ifen (Sigma) suspended in corn oil by oral gavage once daily for 4 consecutive
days.
For T+E2 treatment, a 1.0 cm Silastic capsule (No. 602–305 Silastic tubing;
1.54 mm inside diameter, 3.18 mm outside diameter; Dow-Corning #2415569)
filled with testosterone (Sigma) and a 0.4 cm Silastic capsule filled with estra-
diol-17b (Sigma) were implanted subcutaneously. Mice were treated with hor-
mones for 4 months.
All animal studies were performed using protocols approved by the Institu-
tional Animal Care and Use Committee of Columbia University Medical Center.
Tissue Collection and Flow Cytometry
Prostate tissue dissection, fixation, and dissociation were performed as
described previously (Wang et al., 2013). Cell sorting was performed based
on YFP fluorescence on a BD FACS Aria II instrument in the Flow Cytometry
Shared Resource of the Herbert Irving Comprehensive Cancer Center. We
used side scatter/forward scatter gating to exclude debris and doublets, fol-
lowed by phycoerythrin/YFP fluorescein isothiocyanate A gating to exclude
autofluorescent double-positive cells and to collect the single-positive YFP-
expressing cell population.
Renal Grafting Assay
For tissue recombinants, 1.03 104 dissociated YFP+ cells were mixed with 2.5
3 105 dissociated urogenital sinus mesenchyme cells from embryonic day
18.0 rat embryos. Tissue recombinants were cultured in Dulbecco’s modified
Eagle’s medium/10% fetal bovine serum/107 M dihydrotestosterone over-
night, followed by transplantation under the kidney capsules of immunodefi-
cient NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice (Taconic) and growth
for 12 weeks.
Histology and Immunostaining
Hematoxylin and eosin (H&E) staining and immunofluorescence staining were
performed (Wang et al., 2013) using the following primary antibodies: rabbitCell ReCK5 (Covance #PRB-160P, 1:1,000), rabbit CK8 (Abcam #ab53280, 1:250),
mouse CK18 (Abcam #ab668, 1:100), chick GFP (Abcam #ab13970,
1:2,000), and rabbit phospho-Akt (Cell Signaling #3787, 1:50). Samples were
incubated with secondary antibodies (diluted 1:500 in PBST) labeled with
Alexa 488, Alexa Fluor 555, or Alexa Fluor 647 (Invitrogen/Molecular Probes)
and mounted with VECTASHIELD medium with DAPI (Vector Labs). Immu-
nofluorescence was imaged using a Leica TCS SP5 spectral confocal
microscope.
Data Quantitation
Cell numbers were counted using confocal 340 and 363 photomicrographs.
For histologically normal tissues at 2 months, the percentage of YFP+ cells
(labeled ‘‘Nor’’ in Figures 2Y–2A0 and S1G and ‘‘Cont’’ in Figure 3Q) represents
the ratio of YFP+ cells to total basal or luminal cells. For tumor tissues at later
ages, the percentage of YFP+ cells (labeled ‘‘Tum’’ in Figures 2Y–2A0 and S1G
and ‘‘T+E2’’ in Figure 3Q) represents the ratio of clustered YFP+ cells in tumor
lesions to total epithelial cells within these lesions. Statistical analyses were
performed using a two-sample t test. At least three animals for each experi-
ment or genotype were analyzed.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and three tables and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2014.08.002.
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